Mitogen-activated protein kinase 1, 3, and 8 (MAPK1/3/8)

MAPK1 (ERK2), MAPK3 (ERK1), and MAPK8 (JNK1) are key members of the mitogen-activated protein kinase (MAPK) family, functioning as critical nodes in intracellular signaling networks [UniProt]. ERK1 and ERK2 are primarily activated by mitogenic stimuli via the Ras-Raf-MEK-ERK cascade, where they regulate fundamental processes such as cell growth, proliferation, and survival [NIH]. MAPK8, also known as JNK1, is a stress-activated protein kinase (SAPK) that responds to environmental stressors and inflammatory cytokines, often mediating apoptosis and the inflammatory response [PubMed]. Together, these kinases form a signaling hub that integrates diverse extracellular signals to coordinate cellular fate [ASH Publications]. Dysregulation of this MAPK1/3/8 axis is implicated in various pathologies, including solid tumors, hematological malignancies, and chronic inflammatory conditions like Alzheimer's disease and nephropathy [ResearchGate]. While specific inhibitors for ERK1/2 (e.g., Ulixertinib) and JNK1 (e.g., Tanzisertib) have been developed, the therapeutic challenge lies in managing the complex crosstalk and redundancy within the MAPK pathways to achieve efficacy without significant off-target toxicity [ClinicalTrials.gov].

Other names

ERK1ERK2JNK1Extracellular signal-regulated kinase 1/2c-Jun N-terminal kinase 1MAPK1/3/8 signaling hub

Small-molecule inhibition of kinase activity, typically through ATP-competitive binding to the catalytic domain of the respective kinases (ERK1, ERK2, and JNK1).